Last edition
News about Clinical Trials
The Colorectal Cancer Alliance and the Global Coalition for Adaptive Research have partnered to launch KLEOS, a pioneering adaptive clinical trial platform designed to accelerate the development of new therapies for colorectal cancer and improve patient outcomes.
Clinical Trials | 01/06/2026 | By News Bureau
CARES Phase 3 Trial Highlights Anselamimab Potential in Kappa Light Chain Amyloidosis
Anselamimab demonstrated promising efficacy in the phase 3 CARES programme, showing a 62 percent improvement in survival and a 71 percent reduction in cardiovascular hospitalisations among patients with kappa light-chain amyloidosis, despite the study not meeting its primary endpoint in the overall light-chain amyloidosis population.
Clinical Trials | 01/06/2026 | By News Bureau
Pfizer's BRAFTOVI Nearly Doubles Progression-Free Survival in Metastatic Colorectal Cancer
Pfizer reported phase 3 BREAKWATER trial results showing that the BRAFTOVI regimen nearly doubled median Progression-Free Survival (PFS) in patients with metastatic colorectal cancer, reducing the risk of disease progression or death by 56 percent and the risk of death by 44 percent compared with standard chemotherapy in BRAF V600E-mutant disease.
Clinical Trials | 01/06/2026 | By News Bureau
Bristol Myers Squibb reported Phase 3 SUCCESSOR-2 results showing that mezigdomide reduced the risk of disease progression or death by more than 50% versus standard of care in relapsed or refractory multiple myeloma, marking the first successful Phase 3 CELMoD trial presented at ASCO 2026.
Clinical Trials | 30/05/2026 | By News Bureau
Pfizer's LORBRENA Delivers 7-Year Progression-Free Survival in Advanced NSCLC
Pfizer reported 7-year results from the CROWN trial showing that LORBRENA achieved the longest Progression-Free Survival reported to date in advanced Non-Small Cell Lung Cancer (NSCLC), with 55 percent of patients remaining progression-free at 7 years and median progression-free survival not yet reached.
Clinical Trials | 30/05/2026 | By News Bureau
Ribo Submits Phase 2 EMA Trial Application for siRNA Therapy in Thromboembolic Disease
Ribo submits a Phase 2 clinical trial application to the European Medicines Agency (EMA) for its siRNA therapeutic targeting thromboembolic disease, advancing development of innovative oligonucleotide-based therapies for Coronary Artery Disease (CAD)
Clinical Trials | 28/05/2026 | By News Bureau
Jade Biosciences Doses First Patient in Phase 2 Trial of JADE101 for IgA Nephropathy
Jade Biosciences announces first patient dosing in the phase 2 JUNIPER trial evaluating JADE101 for IgA nephropathy, with interim clinical data expected in 2027.
Clinical Trials | 26/05/2026 | By News Bureau
Phase 2a study findings show RESP-X demonstrated safety, favourable dosing potential and encouraging efficacy signals, supporting further clinical development for respiratory patients colonised with Pseudomonas aeruginosa.
Clinical Trials | 25/05/2026 | By News Bureau
Merck Doses First Patient in Phase 3 Trial of Investigational ADC for Colorectal Cancer
Merck announces first patient dosing in a phase 3 trial evaluating investigational Antibody Drug Conjugate (ADC) precemtabart tocentecan for metastatic colorectal cancer, targeting CEACAM5 expressed in most colorectal tumors.
Clinical Trials | 22/05/2026 | By News Bureau
1st ICMR Clinical Trial Meet 2026 Showcases India's Growing Role in Integrative Medicine Research
The Indian Council of Medical Research (ICMR) Annual Clinical Trial Meet 2026 highlighted India’s growing leadership in integrative medicine research, alongside new initiatives to strengthen phase 1 clinical trials and streamline ethics review for multicenter studies.
Clinical Trials | 21/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy